SELLAS Life Sciences Closes $15M Public Offering
Ticker: SLS · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1390478
| Field | Detail |
|---|---|
| Company | Sellas Life Sciences Group, Inc. (SLS) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: public-offering, financing, healthcare
TL;DR
SELLAS closed its $15M stock offering at $10/share, raising cash for pipeline development.
AI Summary
On March 28, 2024, SELLAS Life Sciences Group, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully raised approximately $15.0 million in gross proceeds before deducting underwriting discounts and commissions and other offering expenses. This offering involved the sale of 1,500,000 shares of common stock at a price of $10.00 per share.
Why It Matters
The successful completion of this offering provides SELLAS Life Sciences with additional capital, which is crucial for funding its ongoing clinical trials and advancing its drug development pipeline.
Risk Assessment
Risk Level: medium — Public offerings can dilute existing shareholders and the success of the company depends on the effective use of the raised capital for drug development.
Key Numbers
- $15.0M — Gross Proceeds (Capital raised from the public offering)
- $10.00 — Price Per Share (The price at which shares were sold in the offering)
- 1.5M — Shares Sold (The total number of shares issued in the offering)
Key Players & Entities
- SELLAS Life Sciences Group, Inc. (company) — Registrant
- March 28, 2024 (date) — Closing date of the offering
- $15.0 million (dollar_amount) — Gross proceeds from the offering
- 1,500,000 (number) — Number of shares sold
- $10.00 (dollar_amount) — Price per share
FAQ
What was the total amount of gross proceeds raised by SELLAS Life Sciences in this offering?
SELLAS Life Sciences Group, Inc. raised approximately $15.0 million in gross proceeds from the underwritten public offering.
What was the price per share for the common stock sold in the offering?
The common stock was sold at a price of $10.00 per share.
How many shares of common stock were sold in the offering?
A total of 1,500,000 shares of common stock were sold in the offering.
When did SELLAS Life Sciences announce the closing of this public offering?
The company announced the closing of the offering on March 28, 2024.
What is the purpose of the capital raised from this offering?
The filing implies the capital will be used for general corporate purposes, which typically includes funding clinical trials and advancing drug development for companies like SELLAS Life Sciences.
Filing Stats: 563 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-03-28 08:45:20
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq St
Filing Documents
- tm2410063d1_8k.htm (8-K) — 27KB
- 0001104659-24-040176.txt ( ) — 196KB
- sls-20240328.xsd (EX-101.SCH) — 3KB
- sls-20240328_lab.xml (EX-101.LAB) — 33KB
- sls-20240328_pre.xml (EX-101.PRE) — 22KB
- tm2410063d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On March 28, 2024, GenFleet Therapeutics (Shanghai), Inc. ("GenFleet"), SELLAS Life Science Group Inc.'s partner with respect to the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, announced that it entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland GmbH to initiate a combination study of GFH009 and BRUKINSA (zanubrutinib, BTK inhibitor) in a multicenter phase Ib/II trial treating diffuse large B-cell lymphoma (DLBCL) and announced the dosing of the first patient in the trial. According to the announcement, under the terms of the clinical trial collaboration and supply agreement, GenFleet will conduct an open-label, single-arm and multi-center study of the combination therapy to evaluate the safety and efficacy among relapsed/refractory DLBCL patients. The study is being conducted in China. The information in this Item 8.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration such filing. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SELLAS Life Sciences Group, Inc. Date: March 28, 2024 By: /s/ John T. Burns Name: John T. Burns Title: Senior Vice President, Chief Financial Officer 3